US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

21.77

+0.77503.69%

Post-market: 22.300.5350+2.46%19:30 EDT

Volume:18.25K

Turnover:396.46K

Market Cap:49.30M

PE:- -

High:21.93

Open:21.18

Low:21.15

Close:20.99

52wk High:27.02

52wk Low:15.63

Shares:2.26M

Float Shares:2.26M

Volume Ratio:0.71

T/O Rate:0.81%

Dividend:1.68

Dividend Rate:7.73%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ono Pharma Advances Pediatric Epilepsy Trial, Bolstering Long-Term Growth Story

GH Research to Present GH001 Depression Trial Data at ECNP 2026 Meeting

Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study

Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50

THOMSON REUTERS

Ballard Mining Launches $45 Million Share Placement and SPP to Fund Gold Projects

Cynata defines target market for new options in capital raising

Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

Clearmind Medicine submits psychedelic therapy recommendations to FDA

TZ Limited shares halted ahead of material capital raising

Canterbury Resources Raises $564,000 to Advance Monto Exploration

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105

NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial

Vaxcyte data hit ‘blue-sky’ case, says Jefferies

Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31

Surefire Resources Plans Placement of 45 Million New Shares

Surefire Resources launches A$2.7m equity raising to advance WA gold projects

Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PSIL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":21.765,"timestamp":1791576000000,"preClose":20.99,"halted":0,"volume":18254,"hourTrading":{"tag":"盘后","latestPrice":22.3,"preClose":21.765,"latestTime":"19:30 EDT","volume":250,"amount":5565.17,"timestamp":1791588604604,"change":0.535,"changeRate":0.024581,"amplitude":0.024581},"delay":0,"changeRate":0.03692234397332073,"floatShares":2264976,"shares":2264976,"eps":0,"marketStatus":"Market Closed","change":0.775,"latestTime":"10-09 16:00:00 EDT","open":21.18,"high":21.925,"low":21.15,"amount":396457.62203,"amplitude":0.036922,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":20.99,"sharesOutstanding":1184976,"nav":21.119,"aum":47833661.17,"dividendRate":0.077344,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.99,"preClose":20.99,"latestTime":"07:00 EDT","volume":16,"amount":335.84,"timestamp":1791543613403,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":22.3,"preClose":21.765,"latestTime":"19:30 EDT","volume":250,"amount":5565.17,"timestamp":1791588604604,"change":0.535,"changeRate":0.024581,"amplitude":0.024581},"volumeRatio":0.7145821100019574,"impliedVol":0.3807,"impliedVolPercentile":0.5896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2264976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7145821100019574,"shares":2264976,"dividePrice":1.6834,"high":21.925,"amplitude":0.036922,"preClose":20.99,"low":21.15,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":21.765,"eps":0,"divideRate":0.077344,"volume":18254,"delay":0,"ttmEps":0,"open":21.18,"prevYearClose":17.17,"prevWeekClose":21.85,"prevMonthClose":22.5,"prevQuarterClose":22.5,"fiveDayClose":21.85,"twentyDayClose":24.7682,"sixtyDayClose":24.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674865909","title":"Ono Pharma Advances Pediatric Epilepsy Trial, Bolstering Long-Term Growth Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2674865909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674865909?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:31","pubTimestamp":1791563500,"startTime":"0","endTime":"0","summary":"ONO Pharmaceutical Co ($OPHLF) announced an update on their ongoing clinical study. Ono Pharmaceutical Co., Ltd. (OPHLF) is running a Phase 3 trial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ono-pharma-advances-pediatric-epilepsy-trial-bolstering-long-term-growth-story?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ono-pharma-advances-pediatric-epilepsy-trial-bolstering-long-term-growth-story?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OPHLF","BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856377","title":"GH Research to Present GH001 Depression Trial Data at ECNP 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856377","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856377?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:02","pubTimestamp":1791543739,"startTime":"0","endTime":"0","summary":"GH Research to present GH001 depression trial data at ECNP 2026 meetingGH Research plc set three posters for ECNP 2026 featuring data from its GH001-TRD-201 and GH001-BD-202 depression trials.Results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL3Qbv87:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4007","BK4539","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674090940","title":"Mirum’s AZURE-2 Trial Pits Brelovitug Against Bulevirtide in High-Stakes Hepatitis D Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2674090940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674090940?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:31","pubTimestamp":1791477107,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals ($MIRM) announced an update on their ongoing clinical study. The AZURE-2 Phase 3 trial from Mirum Pharmaceuticals, Inc. tests...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mirums-azure-2-trial-pits-brelovitug-against-bulevirtide-in-high-stakes-hepatitis-d-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mirums-azure-2-trial-pits-brelovitug-against-bulevirtide-in-high-stakes-hepatitis-d-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079126","title":"Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079126?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457599,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U1FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IBRN","PSIL","FBT","BK4139","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673468070","title":"Ballard Mining Launches $45 Million Share Placement and SPP to Fund Gold Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2673468070","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673468070?lang=en_us&edition=fundamental","pubTime":"2026-10-08 07:37","pubTimestamp":1791416250,"startTime":"0","endTime":"0","summary":"The latest update is out from Ballard Mining Limited ( ($AU:BM1) ). Ballard Mining Limited has launched a capital raising initiative comprising a n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ballard-mining-launches-45-million-share-placement-and-spp-to-fund-gold-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ballard-mining-launches-45-million-share-placement-and-spp-to-fund-gold-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673004531","title":"Cynata defines target market for new options in capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2673004531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673004531?lang=en_us&edition=fundamental","pubTime":"2026-10-08 06:38","pubTimestamp":1791412685,"startTime":"0","endTime":"0","summary":"An announcement from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Cynata Therapeutics has issued a target market determination for n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cynata-defines-target-market-for-new-options-in-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cynata-defines-target-market-for-new-options-in-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673656016","title":"Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673656016","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673656016?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:00","pubTimestamp":1791381622,"startTime":"0","endTime":"0","summary":"WSW, NY, October 7th, 2026, FinanceWire The former Gilead and Amgen commercial leader takes her seat as Entera’s Phase 3 trial nears its init...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/former-gilead-and-amgen-commercial-leader-laura-hamill-just-joined-entera-nasdaq-entx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","IBB","NQmain","MNQmain","BK4566","QDTE","QLD","BK4599","03086","BBC","LU0320765992.SGD","QQQM","TQQQ","ONEQ","JEPQ","TBXU","LU0889565916.HKD","QID","SQQQ","IE0002141913.USD","PBE","BK4534","IE00BJT1NW94.SGD","GPIQ","IE0009355771.USD","BK4139","LU1983299246.USD","LU1057294990.SGD","QQQE","AMGN","PJP","QQQJ","TECS","LU0122379950.USD","PSQ","BIB","NDX","IE00BFTCPJ56.SGD","FTEC","IYW","NVIW.SI","QYLG","BBH","QQQ","QQQA",".IXIC","QQQY","IBBQ","ENTX","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673159350","title":"Clearmind Medicine submits psychedelic therapy recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673159350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673159350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:25","pubTimestamp":1791379525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","PSYK","BK4585","LABU","BK4588","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673660180","title":"TZ Limited shares halted ahead of material capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2673660180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673660180?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:34","pubTimestamp":1791326069,"startTime":"0","endTime":"0","summary":"The latest announcement is out from TZ Limited ( ($AU:TZL) ). TZ Limited has requested and been granted a trading halt on its shares on the Austral...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tz-limited-shares-halted-ahead-of-material-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tz-limited-shares-halted-ahead-of-material-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066214","title":"Canterbury Resources Raises $564,000 to Advance Monto Exploration","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066214?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:10","pubTimestamp":1791324648,"startTime":"0","endTime":"0","summary":"Canterbury Resources Ltd. ( ($AU:CBY) ) just unveiled an update. Canterbury Resources has completed a strategic capital raising of $564,000 via a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/canterbury-resources-raises-564000-to-advance-monto-exploration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/canterbury-resources-raises-564000-to-advance-monto-exploration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051961","title":"ArriVent says Phase 3 firmonertinib trial did not meet endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051961?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:13","pubTimestamp":1791292413,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, loca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","PSIL","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705514","title":"Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705514","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705514?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:35","pubTimestamp":1791286532,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4139","NVIB","HYLG","BBC","PSIL","GDOC","MEDX","IDNA","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084771","title":"NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084771","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084771?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:01","pubTimestamp":1791234103,"startTime":"0","endTime":"0","summary":"NRx Defense Systems wins initial $11.18 million DARPA prime contract for SPARC-TMS depression trialNRx Defense Systems, a NRX Pharmaceuticals unit, won a DARPA prime contract worth USD 11.18 million f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1b0rVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673088978","title":"Vaxcyte data hit ‘blue-sky’ case, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673088978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673088978?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:55","pubTimestamp":1791208523,"startTime":"0","endTime":"0","summary":"After Vaxcyte (PCVX) announced topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating its VAX-31 31-valent pneumococcal conjugate v...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-data-hit-blue-sky-case-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4139","BBC","IE0009354923.USD","PCVX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709724","title":"Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709724","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709724?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:10","pubTimestamp":1791195037,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-announces-positive-results-from-opus-1-phase-3-trial-of-vax-31-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","PCVX","BBC","IE0009354923.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776060","title":"Surefire Resources Plans Placement of 45 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776060?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:32","pubTimestamp":1791156742,"startTime":"0","endTime":"0","summary":"The latest update is out from Surefire Resources NL ( ($AU:SRN) ). Surefire Resources NL has notified the ASX of a proposed capital raising via an ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/surefire-resources-plans-placement-of-45-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/surefire-resources-plans-placement-of-45-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673877609","title":"Surefire Resources launches A$2.7m equity raising to advance WA gold projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2673877609","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673877609?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:32","pubTimestamp":1791156734,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Surefire Resources NL ( ($AU:SRN) ). Surefire Resources NL has launched a capital raising of up to A$2.61 milli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/surefire-resources-launches-a2-7m-equity-raising-to-advance-wa-gold-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/surefire-resources-launches-a2-7m-equity-raising-to-advance-wa-gold-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLD","DGZ","IAU","SGDM","DZZ","GDXY","CEF","KGLD","1OZmain","GBUG","AAAU","BAR","PICK","PPI","SHNY","DULL","GDXD","OUNZ","JDST","FGDL","XME","GDXW","BGLD","JNUG","PSIL","BEGS","GSE","BTGD","GLDM","GLTR","IGLD","UYM","DUST","IAUM","GDXU","UGL","GDXJ","GLDY","SGOL","DBC","GDX","GLL","GOLY","PHYS","YGLD","DGP","RING","USG","IAUI","GOAU","NUGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776067","title":"Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776067?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:22","pubTimestamp":1791156146,"startTime":"0","endTime":"0","summary":"An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported new analyses from its Phase 2 trial of AT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alteritys-ath434-phase-2-data-strengthen-case-for-msa-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672974104","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974104","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974104?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:23","pubTimestamp":1790979782,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $83,464.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Oct. 2, 2026.Sale price USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6fSlzc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","ALKS","IBRN","FBT","MEDX","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}